Basic Female Viagra Information

• INN (International Nonproprietary Name): flibanserin and bremelanotide.
• Brand Names Available In United Kingdom: not specified.
• ATC Code: Flibanserin G02CX01; Bremelanotide G02CX06.
• Forms & Dosages: Flibanserin 100 mg oral tablets (once nightly at bedtime); Bremelanotide 1.75 mg single‑use subcutaneous autoinjector (use as needed, max 8 doses/month).
• Manufacturers In United Kingdom: not specified.
• Registration Status In United Kingdom: not specified.
• OTC / Rx Classification: Prescription only in regulated markets for Addyi and Vyleesi; some sildenafil generics sold OTC in certain other countries.

Instructions, Warnings And Daily-Life Integration

Worried about low sexual desire and not sure where to start?

Talk to your GP, a sexual health clinic or your pharmacist before trying any product advertised as “female viagra”.

Flibanserin (Addyi) and bremelanotide (Vyleesi) are prescription medicines in regulated markets and need clinician assessment before use.

Avoid unregulated sildenafil products from overseas websites that are marketed as “female Viagra” because they are not approved for hypoactive sexual desire disorder and may be unsafe.

Flibanserin can cause low blood pressure and fainting when taken with alcohol and with strong CYP3A4 inhibitors, so do not drink alcohol while taking it and tell your prescriber about all other medicines you take.

Flibanserin is taken at bedtime to reduce daytime drowsiness and dizziness.

Bremelanotide is an on‑demand subcutaneous injection given at least 45 minutes before sex, stored at room temperature and discreet to carry.

Use NHS services (GP or sexual health clinic) for assessment and prescription where available.

Prescription charges apply in England but are free in Scotland, Wales and Northern Ireland.

Community pharmacies such as Boots, LloydsPharmacy and Superdrug can dispense and counsel where supply is available.

Quick Safety Checklist

• Discuss low desire with a GP, sexual health clinic or pharmacist before trying medication.
• Do not use flibanserin with alcohol or strong CYP3A4 inhibitors.
• Avoid if you have severe liver impairment or are pregnant or breastfeeding.
• Report fainting, severe dizziness, severe nausea or chest symptoms promptly to your prescriber.
• Avoid unregulated overseas sellers of “female Viagra” tablets that are actually sildenafil.

Where To Get Help

Everyday Use & Best Practices

Morning Vs Evening Dosing

Flibanserin is taken once a day at bedtime to keep drowsiness and dizziness from interfering with daytime activities.

Taking flibanserin at night fits common UK routines—after the evening meal and before bed—so commuting or office work is less likely to be affected.

Bremelanotide is an as‑needed injection given at least 45 minutes before anticipated sexual activity and can be carried discreetly in a handbag.

Plan first doses at quieter times to judge how you feel, and avoid scheduling important driving or safety‑sensitive tasks during the first week of treatment if you start feeling drowsy or dizzy.

Taking With Or Without Meals (UK Diet Habits)

Flibanserin should be taken at the same time every night regardless of food, but absolute avoidance of alcohol with the dose is essential for safety.

A typical heavier UK evening meal does not change bedtime dosing, but be mindful that alcohol portion sizes with dinner can increase the risk of hypotension when combined with flibanserin.

For Vyleesi injections, plan privacy and a clean area for administration and carry a sharps container or arrange disposal at a pharmacy or clinic after use.

Step‑by‑step dosing checklist:

• Flibanserin: 100 mg by mouth once nightly at bedtime; skip missed doses—do not double up.
• Vyleesi: 1.75 mg subcutaneous injection ≥45 minutes before sex; max 1 dose per 24 hours and 8 doses per month.
• Always tell the prescriber about other medicines and alcohol use before starting.

Pre‑injection prep checklist for Vyleesi:

• Wash hands and clean the injection site.
• Confirm you have no recent high blood pressure or cardiovascular symptoms.
• Carry out injection as instructed and store used sharps safely for disposal.

Safety Priorities

Who Should Avoid It (MHRA Warnings)

Flibanserin must not be used in people with severe liver impairment.

Do not take flibanserin if you drink alcohol because of the risk of low blood pressure and fainting.

Avoid flibanserin with strong CYP3A4 inhibitors such as certain antifungals, macrolide antibiotics and some antivirals unless advised by a specialist.

Bremelanotide should be used with caution in people with cardiovascular disease as it can raise blood pressure transiently.

Neither product is indicated for those under 18 or for pregnant or breastfeeding women.

Activities To Limit (Driving, Work Safety)

Avoid driving or operating heavy machinery if you feel dizzy or drowsy after starting a medicine for low desire.

Consider arranging lighter duties for the first week of flibanserin so you can monitor for somnolence or dizziness.

If fainting, severe dizziness or severe nausea occur, stop the medication and contact your GP, NHS 111 or attend A&E depending on severity.

Pharmacists should advise cessation of alcohol with flibanserin and prompt reporting of serious adverse effects to the prescriber and via the MHRA Yellow Card where appropriate.

Dosage & Adjustments

General Regimen (NHS Guidance)

Flibanserin standard dosing is 100 mg orally once nightly at bedtime; reassess benefit and tolerability around eight weeks.

Bremelanotide standard dosing is 1.75 mg by subcutaneous injection at least 45 minutes before sexual activity, maximum one dose in 24 hours and eight doses in a 30‑day period.

GPs or sexual health clinics will confirm a diagnosis of acquired, generalized hypoactive sexual desire disorder before considering these options.

Special Cases (Elderly, Comorbidities)

Flibanserin is not recommended in people over 65 due to limited safety and efficacy data in this group.

Flibanserin is contraindicated in severe hepatic impairment; moderate impairment requires caution and specialist advice.

Bremelanotide requires caution in patients with hepatic or renal impairment and in those with cardiovascular risk factors where blood pressure monitoring may be needed.

Missed dose instructions:

• Flibanserin: If a dose is missed, skip it and take the next dose at the usual time; do not double dose.
• Bremelanotide: Do not inject a missed planned dose; follow prescriber advice.

User Testimonials

Positive Reports From UK Patients

Some premenopausal women in UK reports mention a measurable increase in sexual desire and improved relationship satisfaction after several weeks on flibanserin.

Other patients prefer bremelanotide because the on‑demand injection gives more control and spontaneity for individual encounters.

Patients value clear pharmacist counselling about alcohol risks and interactions before starting treatment.

Common Challenges (Patient.info, NHS Forums)

Commonly reported issues on UK forums include early daytime drowsiness with flibanserin and nausea with bremelanotide.

Access can be frustrating for some because flibanserin was not approved in the EU as of early 2021 and prescribers may be cautious.

Patients sometimes describe paying privately or seeking specialist clinics when NHS access is limited.

• Pros: Potential improvement in desire for some; prescription oversight; tailored choices between nightly or on‑demand options.
• Cons: Modest effect size for some people; side effects such as dizziness, somnolence or nausea; access barriers.

“I felt more interested after about six weeks, but the first fortnight I needed to be careful about driving.”

Buying Guide

Pharmacy Sources (Boots, LloydsPharmacy, Superdrug)

These medicines are prescription only and must be supplied by a GP, sexual health clinic or private clinic and dispensed at community pharmacies where stocked.

Addyi and Vyleesi are marketed in the United States, and flibanserin is not widely approved in the EU as of early 2021, so availability in UK pharmacies may be limited and often relies on specialist or private prescriptions.

In our online pharmacy, female viagra is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Price Comparison (NHS Prescription Charge Vs Private)

On the NHS, prescription charges apply in England per item unless exempt, while prescriptions are free in Scotland, Wales and Northern Ireland.

Private consultation fees and drug costs vary widely depending on clinic and supplier, and some patients choose private imports under clinician supervision where permitted.

Safe buying checklist:

• Only take medicine supplied with a valid prescription from a recognised clinician.
• Avoid unregulated overseas sellers advertising “female Viagra” that are actually sildenafil tablets.
• Ask your pharmacist for counselling on storage, disposal and interactions.

What’s Inside & How It Works

Ingredients Overview

Flibanserin acts on central neurotransmitters as a 5‑HT1A agonist and 5‑HT2A antagonist to modulate serotonin and other brain chemicals.

Bremelanotide is a melanocortin receptor agonist given as a subcutaneous injection to activate neural pathways linked to sexual response.

Sildenafil is a PDE5 inhibitor affecting genital blood flow for erectile dysfunction in men and is not approved for HSDD in women.

Mechanism Basics Explained Simply

Flibanserin works every night to change brain chemistry in a way that may increase spontaneous desire over weeks.

Bremelanotide works quickly on neural circuits when used before an encounter to increase sexual response for that event.

Analogy: Think of flibanserin as a slow‑acting adjustment to the brain’s “mood thermostat” and bremelanotide as a short‑term switch you flip before sex.

Main Indications

Approved Uses (MHRA Listing)

Flibanserin and bremelanotide are approved by the FDA for acquired, generalized hypoactive sexual desire disorder in premenopausal women as prescription medicines.

Regulatory approval in the EU/UK has been cautious, and flibanserin was not approved in the EU as of early 2021.

Off‑Label Uses In UK Clinics

Specialist clinics or private prescribers may consider off‑label use or alternative therapies after detailed assessment and informed consent.

Prescriber checklist:

• Document a confirmed HSDD diagnosis after assessment.
• Obtain informed consent explaining modest benefits and risks.
• Perform baseline liver and cardiovascular checks where indicated.

Interaction Warnings

Food Interactions (Alcohol, Tea/Coffee)

Alcohol with flibanserin can cause severe hypotension and syncope and must be avoided while taking the drug.

Caffeine from tea or coffee is not a direct contraindication but may worsen insomnia if combined with somnolence‑prone medicines.

Drug Conflicts (MHRA Yellow Card Reports)

Strong CYP3A4 inhibitors markedly increase flibanserin levels and are contraindicated; examples include some azole antifungals, macrolide antibiotics and certain antivirals.

Bremelanotide can raise blood pressure transiently and should be used with caution if the patient is taking antihypertensive medicines.

Pharmacists should encourage patients to report severe dizziness, fainting or hypertensive episodes via the MHRA Yellow Card scheme and to their prescriber.

Latest Evidence & Insights

Key UK & EU Studies 2022–2025

Recent trial data continue to show modest efficacy for both flibanserin and bremelanotide in premenopausal women with HSDD, with tolerability issues such as dizziness, somnolence or nausea reported.

Head‑to‑head comparisons remain limited and longer‑term real‑world safety data continue to be collected.

EU and UK regulatory bodies have been cautious and clinicians often rely on published international trials when considering private prescribing.

Practical Learnings For Clinicians

Select patients carefully, screen for alcohol use and liver disease, set realistic expectations and schedule an early review around eight weeks for flibanserin to assess benefit and side effects.

Principal trial outcomes summarised:

• Modest improvements in validated desire measures for some patients.
• Common adverse effects include dizziness, somnolence (flibanserin) and nausea (bremelanotide).
• Effect sizes vary between individuals and some discontinue due to side effects.

GP takeaway: document the rationale, obtain informed consent and monitor closely after initiation.

Alternative Choices

NHS Prescribing Alternatives With Pros/Cons Checklist

Begin with a full assessment to identify reversible causes before considering pharmacotherapy.

• Treat hormonal causes such as menopausal genitourinary symptoms with local oestrogen where appropriate — pros: addresses local symptoms; cons: does not directly target central desire pathways.
• Review and adjust medications that may reduce libido where possible — pros: removes reversible cause; cons: alternative meds may not be suitable for all conditions.
• Refer for psychosexual therapy or couples counselling — pros: addresses psychological and relationship factors; cons: waiting times and variable access.

Non‑Pharmacological Options (Therapy, Lifestyle)

Lifestyle measures include regular exercise, better sleep, reducing alcohol and stress management, which can all support sexual health.

Sensate‑focus exercises, relationship counselling and CBT can be effective and are often recommended before or alongside drug therapy.

“Natural” supplements such as maca, ginseng or L‑arginine have limited evidence and variable regulation, so discuss risks and interactions with a clinician before use.

Stepwise management checklist:

1. Assess and treat reversible medical causes.
2. Offer psychosexual therapy or relationship support.
3. Consider hormonal options for menopausal causes.
4. Reserve pharmacotherapy for selected patients after careful discussion.

Regulation Snapshot

MHRA Approval & NHS Prescribing Framework

Both flibanserin and bremelanotide are FDA‑approved for premenopausal women with acquired, generalized HSDD as prescription medicines.

Flibanserin was not approved in the EU as of early 2021 and MHRA guidance in the UK has been cautious, so clinicians should follow local governance for any private prescribing.

GPs should document the diagnosis, discuss risks and benefits, arrange baseline liver and cardiovascular checks and set follow‑up appointments where prescribing occurs.

International Differences (FDA Vs EMA/UK)

The FDA in the United States has approved Addyi and Vyleesi for HSDD while the EMA and MHRA have taken a more cautious stance, reflected in limited approvals in the EU as of early 2021.

Clinicians prescribing privately in the UK should ensure informed consent and local governance arrangements are in place.

FAQ

Common UK Patient Questions

• Can I get “female Viagra” on the NHS?
• A: Not routinely — availability depends on prescriber judgement and regulatory status; discuss options with your GP or sexual health clinic.
• Is it safe with my other medicines?
• A: Review with your GP or pharmacist — flibanserin interacts with alcohol and strong CYP3A4 inhibitors; bremelanotide can affect blood pressure.
• How long before I see results?
• A: Flibanserin is usually reassessed around eight weeks; bremelanotide has an immediate effect when used before sex for individual encounters.
• Are online “female Viagra” tablets the same?
• A: Often not — many online products contain sildenafil, which is not approved for HSDD in women; avoid unregulated sellers.

When To Contact NHS Services Checklist:

• Fainting or loss of consciousness.
• Severe dizziness, chest pain or sudden severe headache.
• Severe or persistent nausea or vomiting.

Guidelines For Proper Use

UK Pharmacist Counselling Style

Confirm the prescription is valid and the indication is documented as HSDD.

Explain the dose and timing clearly: flibanserin 100 mg nightly at bedtime; Vyleesi 1.75 mg SC at least 45 minutes before sex.

Emphasise the absolute prohibition on alcohol with flibanserin and list common side effects such as dizziness, somnolence, nausea, headache and flushing.

Advise on missed doses, safe sharps disposal for Vyleesi and document any questions in the patient record.

NHS Patient Support Advice

Refer patients back to their GP or sexual health clinic for multidisciplinary care including psychosexual therapy or couples counselling.

Remind patients about prescription charges in England versus free prescriptions in Scotland, Wales and Northern Ireland.

Signpost patients to recognised pharmacy chains for follow‑up and to report adverse events via the MHRA Yellow Card scheme.

Provide a short patient leaflet template listing dose, timings, what to avoid (alcohol), common side effects and contact details for urgent problems.

Delivery Across United Kingdom